Abstract: The invention relates to DL-hydroxyphenylamino acid esters of formula ##STR1## wherein n is 3 to 12 andm is 2 or 3.The compounds are useful as therapeutic agents having antiinflammatory, analgesic, antiallergic and antiasthmatic properties, and also as cosmetic compositions.

Abstract: Pharmaceutical compositions, which comprise a compound of the general formula I ##STR1## in which X is oxygen, sulfur or -CH.sub.2 -, Y is chlorine or bromine, Z is an SO.sub.2 H, NO.sub.2 or C.sub.1 -C.sub.4 alkyl radical, r is a number from 0 to 3, o is a number from 0 to 3, p is the number 0 or 1, m is the number 1 or 2 and n is the number 0 or 1, have having a lipoxygenase- and prostaglandin H synthase-inhibiting action.The compositions are useful in particular for the local (topical) or inhalative treatment of inflammatory, allergic and spasmolytic diseases, as well as psoriasis, bronchial asthma and diseases with disturbances in cell proliferation.

Abstract: Improved bioavailability, particularly when the drug is administered orally, of the active ingredient 2-hydroxy-5-methyllaurophenoxime (HMLO) of a pharmaceutical preparation is achieved by improving the absorption of the active ingredient HMLO significantly by including bile acids in the preparation. As bile acids, it is possible to use, for example, desoxychloic acid or dehydrocholic acid or a mixture of the two in the form of their salts.

Abstract: New 1-(2-hydroxylaryl)-alkane-1-on-oximes, procedure for their preparation, and their applicability to pharmaceutical preparations. One purpose is to develop 1-(2-hydroxyaryl)-alkane-1-on-oximes with desirable pharmacological properties. The new compounds of Formula I ##STR1## are characterised by pharmacologically valuable properties, in particular by anti-asthmatic, anti-anaphylactic, antiphlogistic, antihypertensive, spasmolytic, antirheumatic, and antithrombotic, potentials and are applicable in human and veterinary medicine to therapy of asthma bronchiale and other allergic diseases, various kinds of inflammatory and rheumatic diseases, and thrombosis.

Abstract: Hydroxamic acids, pharmaceutical preparations containing the same, new .omega.(2'-naphthoxy)-alkylhydroxamic acids as well as a process for their production are disclosed. The new compounds display antiasthmatic and further pharmacologically valuable characteristics. They are prepared by reacting the corresponding carboxylic acid ester or amide with hydroxylamine or its salt under the described conditions into compounds of Formula I,R--CO--NH--OH.The compounds of Formula I are useful in human and veterinary medicine as medicaments the active principal of which is the inhibition of lipoxygenase, thus as antiasthmatic, antianaphylactic, antiphlogistic, antirheumatic and antithrombotic preparations.